Samantha Hawkins is a Privacy and Data Security Reporter at Bloomberg Law. She focuses on topics such as lawsuits, ESG, and developments in California, Oregon, and Nevada, providing in-depth analysis on the intersection of privacy laws and data security. Her work has been featured in Bloomberg Law, Building Salt Lake, and Mintz.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Samantha Hawkins' articles predominantly focus on legal policy, government announcements, and their implications for land management, environmental protection, and related legal challenges. She might be interested in receiving pitches that offer insights into ongoing or upcoming litigation involving environmental protection agencies or challenges to government policies relating to land use.
Given her coverage attributes and themes covered, Samantha would likely welcome input from experts who can provide analysis of the legal aspects of environmental regulations, particularly as they pertain to agriculture, energy production, and natural resource management. Additionally, she may find value in commentary related to business impacts resulting from these regulatory developments.
As Samantha's geographic focus is not specified but her topics often relate to specific regions like Nevada and Arizona mentioned in the article titles suggest a potential interest in local impact stories within the United States.
This information evolves through artificial intelligence and human feedback. Improve this profile .
A developer lost its bid for a proposed development in Sandy after a board upheld the city's decision that the project didn’t meet city code.
By: Samantha Hawkins
The Salt Lake City-owned Northwest Pipeline Building will be transformed into a mixed-use building with units available for lease by 2025.
By: Tara E. Dwyer, Samantha Hawkins
As part of its 2025 Medicare Advantage and Part D Final Rule (the Final Rule), the Centers for Medicare & Medicaid Services (CMS) finalized a number of regulatory changes relating to how Medicare Advantage (MA) plans offer supplemental benefits and how they communicate such benefits to plan members. As previewed in the Proposed 2025 Rules
By: Samantha Hawkins
Cities along the Wasatch Front are cutting hurdles so homeowners can offer a housing solution: small rental properties in the backyard.
By: Rachel A. Alexander, Tara E. Dwyer, Theresa C. Carnegie, Joseph M. Miller, Bridgette A. Keller, Samantha Hawkins, Hassan Shaikh, Payton T. Thornton
On July 9, 2024, the Federal Trade Commission (FTC) Office of Policy Planning released an Interim Staff Report titled Pharmacy Benefit Managers: The Powerful Middlemen Inflating Drug Costs and Squeezing Main Street Pharmacies
By: Rachel A. Alexander, Theresa C. Carnegie, Mitchell J. Clough, Tara E. Dwyer, David R. Gilboa, Xavier G. Hardy, Samantha Hawkins, Stephnie A. John, Bridgette A. Keller, Lauren M. Moldawer, Hassan Shaikh
Mintz’s Pharmacy Benefits and PBM Contracting Practice is pleased to present the ‘Third Edition: Q2 2024’ of our Mintz IRA Update, a regular publication that delves into developments of the Inflation Reduction Act of 2022 (IRA) and their impact on pharmaceutical supply chain stakeholders.
By: Tara E. Dwyer, Lauren M. Moldawer, David R. Gilboa, Samantha Hawkins, Stephnie A. John, Matthew Tikhonovsky
The passage of the Inflation Reduction Act of 2022 (IRA) marked a significant milestone in Congress’s ongoing efforts to address escalating health care costs. While the IRA aims to rein in government spending on Medicare and to lower point-of-sale prescription drug costs for Medicare beneficiaries, its implementation, and adoption of the redesigned Medicare Part D program has sparked a cascade of consequences for Medicare Part D plan sponsors (“PDPs”), beneficiaries, and manufacturers.
By: Stephnie A. John, Samantha Hawkins
Since our last edition of the Mintz IRA Update, the Medicare Drug Price Negotiation Program (the “Negotiation Program” or “Program”) and related maximum fair price (MFP) negotiation process for each of the 10 high-expenditure Medicare Part D drugs selected for negotiation (the “Selected Drugs”) has gone into full swing. After the Centers for Medicare and Medicaid Services (CMS) sent initial offers to the manufacturers participating in the first cycle of the Negotiation Program, the Biden administration confirmed that
By: Theresa C. Carnegie, Tara E. Dwyer, Rachel A. Alexander, Bridgette A. Keller, Madison M. Castle, David R. Gilboa, Xavier G. Hardy, Samantha Hawkins, Stephnie A. John, Pat G. Ouellette, Alison H. Peters, Hassan Shaikh, Sophia Temis
Mintz’s PBM practice is pleased to present a 2024 year-to-date PBM Policy and Legislative Update. This edition builds upon prior issues and summarizes activity from January through June that impacts the PBM industry. It specifically highlights federal legislative activity and oversight, state legislation and litigation, and other noteworthy events and trends affecting the PBM industry.
By: Samantha Hawkins
A new development proposal aims to bring additional housing to the Lower Avenues by adding five residential units behind a historic 1950’s fourplex, according to…
(833) 317-6278 
